secwatch.observer — SEC 8-K summary
======================================

Issuer:     Century Therapeutics, Inc. (IPSC)
CIK:        0001850119
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001104659-25-078617
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Century Therapeutics Q2 net loss $32.5M; cash runway into Q4 2027; CEO named Board Chair
--------------------------------------------------------------------------------

- Net loss of $32.5M for Q2 2025 (vs. $31.2M in Q2 2024); cash & equivalents $158.5M as of June 30.
- Cash runway extended into Q4 2027 after workforce reduction completed July 2025.
- CEO Brent Pfeiffenberger appointed Board Chair; Joseph Jimenez steps down, becomes special advisor.
- CNTY-101 CALiPSO-1 trial dosing two patients; clinical data expected by year-end 2025.
- CNTY-308 enters IND-enabling studies; clinical start planned in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850119/000110465925078617/0001104659-25-078617-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850119/000110465925078617/tm2523439d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-078617

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer